Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
ColitisMucositisAML
Interventions
DIETARY_SUPPLEMENT

omegaven

Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.

Trial Locations (1)

3010

University Hospital Inselspital, Bern

All Listed Sponsors
lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT00533078 - Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies | Biotech Hunter | Biotech Hunter